Physician profile
Mohammad Jafferany
NPI 1811008139
$10,012.38
in general payments reported to CMS, 2019-2025
23 companies · $4,887 in 2025
The $4,887 reported for 2025 was more than what 97% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,255 · 2020: $915 · 2021: $925 · 2022: $15.19 · 2023: $15.45 · 2025: $4,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,870 · Travel and Lodging: $1,017 · Education: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,870.00 |
| Travel and Lodging | $1,016.84 |
| Education | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $4,886.84 | 2025 | |
| Allergan, INC. | $2,623.76 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $476.03 | 2019-2023 | Rexulti |
| Lundbeck LLC | $332.72 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $295.00 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $190.39 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $182.00 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $177.81 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $150.66 | 2019-2021 | |
| Shire North American Group INC | $123.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $117.49 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $112.75 | 2019-2020 | |
| Abbvie INC. | $93.88 | 2021 | |
| Vertical Pharmaceuticals, LLC | $46.42 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.08 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $31.57 | 2020-2021 | |
| Tris Pharma INC | $30.36 | 2020 | |
| Owp Pharmaceuticals, INC. | $26.48 | 2019-2020 | |
| Alkermes, INC. | $21.24 | 2021 | |
| Validus Pharmaceuticals LLC | $15.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.59 | 2019 | |
| Neos Therapeutics, Lp | $14.56 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Jafferany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.